Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Share :
Published: 16 Dec 2012
Views: 3204
Rating:
Save
Professor Meletios Dimopoulos - University of Athens, Greece

Prof Dimopoulos presents findings during a press conference at the ASH 2012 Annual Meeting in Atlanta, Georgia on pomalidomidedata with low-dose vs. high-dose dexamathasone in refractory patients, and the pomalidomide data with numerous newer agents.  Also data with the oral proteasome inhibitors, such as MLN9708, and novel monoclonal antibody agents, such as daratumumab.